SecBot SecBot
PRESS-RELEASE ·Filed Sep 1, 2026

TLX

Telix Pharmaceuticals Limited
BULLISH
Impact 6/10
Horizonmonths Processed2mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Monitor for BiPASS top-line data readout and NDA submission timeline. The FDA alignment de-risks the regulatory pathway, but approval is not guaranteed. If positive, this could transform Telix's imaging franchise by moving PSMA-PET into the initial diagnostic setting, expanding the patient pool well beyond current staging/recurrence indications.

DirectionBullish
Confidencehigh
Horizonmonths

Drug in focus

TLX drug pipeline →

Gozellix

▲ Bullish Named in this press release
Impact
Phase
Approved (FDA, March 21, 2025 — NDA 219592, 505(b)(2))
Time to market
Already marketed — FDA approved March 21, 2025; US commercial launch announced June 2025
Next catalyst
None dated

What to watchGozellix is an already-approved, launched product, so there is no approval binary left to trade, the investor angle is commercial execution. Watch Telix's quarterly revenue disclosures (FY2026 guidance of ~US$950-970M plus US$40M Regeneron other income, Q2 2026 reported Aug 20, 2026) and any market-share data vs. Lantheus' PYLARIFY and Telix's own Illuccix, since Gozellix partly cannibalizes its sibling product. Bigger single-stock moves in TLX over the next year are more likely to come from the therapy pipeline (ProstACT Phase 3) than from this imaging agent.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$11.45
T+0 close · Sep 1, 2026 · via day close
Latest settled
−4.19%
T+20 · $10.97 · next T+60 in 10d
Vs SPY
−3.86%
α at T+20
Latest observation
−12.50%
T+50 · FF3 residual α
  1. T+0 · Sep 2 $11.45entry
  2. T+1 · 3mo ago +2.53%α +1.49% · $11.74
  3. T+5 · 2mo ago +3.93%α +4.89% · $11.90
  4. T+20 · 7w ago −4.19%α −3.86% · $10.97
  5. T+52 · todayOpen
  6. T+60 · in 10d Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Telix completed enrollment (350 patients) in the Phase 3 BiPASS study evaluating Illuccix/Gozellix for pre-biopsy prostate cancer imaging, and aligned with the FDA on an NDA pathway. If successful, this could expand PSMA-PET imaging to a substantially larger patient population (3M biopsies/year globally, up to 75% negative), representing a significant label expansion opportunity for Telix's commercial imaging franchise.

Key Facts

  • Phase 3 BiPASS study completed enrollment of 350 patients in the U.S. and Australia
  • FDA alignment on NDA pathway for pre-biopsy prostate cancer imaging indication
  • Prior PRIMARY/PRIMARY2 studies showed 68Ga-PSMA-PET + MRI can reduce unnecessary biopsies by ~50%
  • Globally >3M prostate biopsies/year; up to 75% are negative, representing a large addressable market expansion
  • Illuccix and Gozellix are already FDA-approved for staging and recurrence imaging; pre-biopsy would be a new product with separate reimbursement

Financial Impact

No financial data provided; potential to significantly expand addressable patient population for Telix's commercial PSMA-PET imaging agents, but revenue impact contingent on BiPASS data and FDA approval

revenuemarket access

Risk Factors

  • BiPASS may fail to meet primary endpoints (diagnostic accuracy vs. standard of care)
  • FDA may require additional data or reject the NDA despite alignment
  • Competition from other PSMA-PET agents and alternative diagnostic approaches
  • Reimbursement hurdles for new pre-biopsy indication

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3354739

Track record

27 reports on TLX

Performance horizon

9 of 20 bullish or bearish reports moved the stock their way by T+1. Best: +29.26% at T+20 after the Jun 1, 2026 report. 18 of 20 went positive at some point.

Filters
  1. Oct 29, 202618d ago 6-K Neutral 5/10 Entry $9.10 to $9.05 Now $8.92 −1.98% ▼ −0.55% −0.07% vs SPY
  2. Oct 20, 202627d ago 6-K Neutral 4/10 No price data
  3. Oct 20, 202627d ago Press Release Bullish 6/10 Entry $10.03 to $9.54 Now $8.92 −11.07% ▼ −4.89% −3.70% vs SPY
  4. Sep 29, 20266w ago 6-K Bullish 6/10 Entry $10.97 to $10.72 Now $8.92 −18.69% ▼ −2.28% −2.46% vs SPY
  5. Sep 21, 20268w ago 6-K Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
  6. Sep 20, 20268w ago Press Release Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
  7. Sep 14, 20269w ago 6-K Bullish 8/10 Entry $12.83 to $11.83 Now $8.92 −30.48% ▼ −7.79% −7.35% vs SPY
  8. Sep 14, 20269w ago Press Release Bullish 8/10 Entry $11.78 to $12.83 Now $8.92 −24.28% ▲ +8.91% +9.37% vs SPY
  9. Sep 1, 202610w ago 6-K Bullish 7/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
  10. Sep 1, 202610w ago Press Release Bullish 6/10 Viewing Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens Wed (10h 17m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 1, 2026